Risk profiles and penetrance estimations in multiple endocrine neoplasia type 2A caused by germline RET mutations located in exon 10
暂无分享,去创建一个
Martin Fassnacht | Marta Barontini | Gabriela Sanso | Charis Eng | Giuseppe Opocher | Mihaela Muresan | M. Hüfner | C. Fauth | C. Eng | M. Fassnacht | H. Neumann | M. Alevizaki | M. Walter | C. Mian | L. Rybicki | J. D. de Groot | A. Patócs | A. Maia | T. Links | G. Valk | T. Musholt | F. Raue | C. Wüster | H. Golcher | Maria Alevizaki | H. Siggelkow | G. Opocher | K. Frank‐Raue | M. Kerstens | N. Wohllk | B. Bendlova | M. Barontini | G. Sansó | Attila Patocs | Konstanze Miehle | Mariola Peczkowska | Christine Fauth | Christian Wüster | Bela Bendlova | Heiko Schweizer | R. Toledo | K. Miehle | Karin Frank‐Raue | Lisa A. Rybicki | Zoran Erlic | Aurelia Winter | Ioana Milos | Sergio P.A. Toledo | Rodrigo A. Toledo | Marcos R. Tavares | Caterina Mian | Heide Siggelkow | Michael Hüfner | Nelson Wohllk | Šárka Dvořáková | Małgorzata Czetwertynska | Elżbieta Skasko | Christian Vorländer | Ana Luiza Maia | Thera P. Links | Jan Willem de Groot | Michiel N. Kerstens | Gerlof D. Valk | Thomas J. Musholt | Josefina Biarnes | Svetozar Damjanovic | Henriette Golcher | Martin A. Walter | Josef Pichl | Friedhelm Raue | Hartmut P.H. Neumann | S. Toledo | H. Schweizer | Z. Erlic | S. Dvorakova | M. Mureşan | C. Vorländer | S. Damjanović | M. Czetwertyńska | J. Biarnés | M. Tavares | E. Skasko | J. Pichl | M. Peczkowska | A. Winter | Ioana Milos | I. Milos
[1] H. Gharib,et al. Medullary thyroid cancer: management guidelines of the American Thyroid Association. , 2009, Thyroid : official journal of the American Thyroid Association.
[2] A. Vortmeyer,et al. Evidence of MEN-2 in the original description of classic pheochromocytoma. , 2007, The New England journal of medicine.
[3] A. Pinchera,et al. RET genetic screening in patients with medullary thyroid cancer and their relatives: experience with 807 individuals at one center. , 2007, The Journal of clinical endocrinology and metabolism.
[4] C. Eng,et al. Clinical Predictors and Algorithm for the Genetic Diagnosis of Pheochromocytoma Patients , 2009, Clinical Cancer Research.
[5] C. Deal,et al. Prophylactic thyroidectomy in pediatric carriers of multiple endocrine neoplasia type 2A or familial medullary thyroid carcinoma: mutation in C620 is associated with Hirschsprung's disease. , 2007, Journal of pediatric surgery.
[6] S. Borrego,et al. The RET C620S mutation causes multiple endocrine neoplasia type 2A (MEN2A) but not Hirschsprung disease (HSCR) in a family cosegregating both phenotypes , 2003, Human mutation.
[7] P. Bernante,et al. Characterization of the largest kindred with MEN2A due to a Cys609Ser RET mutation , 2009, Familial Cancer.
[8] M. Santoro,et al. Molecular mechanisms of RET activation in human neoplasia , 1999, Journal of endocrinological investigation.
[9] C. Eng,et al. Distinct clinical features of paraganglioma syndromes associated with SDHB and SDHD gene mutations. , 2004, JAMA.
[10] H. K. V. van Amstel,et al. Familial medullary thyroid carcinoma: not a distinct entity? Genotype-phenotype correlation in a large family. , 1996, The American journal of medicine.
[11] R. Weigel,et al. When Is Prophylactic Thyroidectomy Indicated for Patients with the RET Codon 609 Mutation? , 2009, Annals of Surgical Oncology.
[12] L. Sobin,et al. TNM Classification of Malignant Tumours , 1987, UICC International Union Against Cancer.
[13] H. Buhr,et al. Long-term outcome in 46 gene carriers of hereditary medullary thyroid carcinoma after prophylactic thyroidectomy: impact of individual RET genotype. , 2006, European journal of endocrinology.
[14] S. Borrego,et al. RET genotypes comprising specific haplotypes of polymorphic variants predispose to isolated Hirschsprung disease , 2000, Journal of medical genetics.
[15] M. Schlumberger,et al. Prognostic factors for survival and for biochemical cure in medullary thyroid carcinoma: results in 899 patients , 1998 .
[16] M. Schlumberger,et al. Prognostic factors for survival and for biochemical cure in medullary thyroid carcinoma: results in 899 patients. The GETC Study Group. Groupe d'étude des tumeurs à calcitonine. , 1998, Clinical endocrinology.
[17] H. Siggelkow,et al. Presentation of a kindred with familial medullary thyroid carcinoma and Cys611Phe mutation of the RET proto-oncogene demonstrating low grade malignancy. , 2001, European journal of endocrinology.
[18] S. Hauptmann,et al. Modification of multiple endocrine neoplasia 2A phenotype by cell membrane proximity of RET mutations in exon 10. , 2008, Endocrine-related cancer.
[19] F. Nielsen,et al. Is thyroidectomy necessary in RET mutations carriers of the familial medullary thyroid carcinoma syndrome? , 2000, Cancer.
[20] J. Strauchen. Germ-line mutations in nonsyndromic pheochromocytoma. , 2002, The New England journal of medicine.
[21] M. Pembrey,et al. Family screening in medullary thyroid carcinoma presenting without a family history. , 1988, The Quarterly journal of medicine.
[22] John P. Bilezikian,et al. CONSENSUS: Guidelines for Diagnosis and Therapy of MEN Type 1 and Type 2 , 2001 .
[23] D. Easton,et al. RISK ESTIMATION AND SCREENING IN FAMILIES OF PATIENTS WITH MEDULLARY THYROID CARCINOMA , 1988, The Lancet.
[24] B. Kennedy,et al. Cancer staging. , 1979, JAMA.
[25] C. Eng,et al. Age-related neoplastic risk profiles and penetrance estimations in multiple endocrine neoplasia type 2A caused by germ line RET Cys634Trp (TGC>TGG) mutation. , 2008, Endocrine-related cancer.
[26] S. Borrego,et al. Specific polymorphisms in the RETproto-oncogene are over-represented in patients with Hirschsprung disease and may represent loci modifying phenotypic expression , 1999, Journal of medical genetics.
[27] B. Ponder,et al. Guidelines for diagnosis and therapy of MEN type 1 and type 2. , 2001, The Journal of clinical endocrinology and metabolism.
[28] F. Wright,et al. A founding locus within the RET proto-oncogene may account for a large proportion of apparently sporadic Hirschsprung disease and a subset of cases of sporadic medullary thyroid carcinoma. , 2003, American journal of human genetics.
[29] R. DeLellis. Pathology and genetics of tumours of endocrine organs , 2004 .
[30] Charis Eng,et al. Cancer phenomics: RET and PTEN as illustrative models , 2007, Nature Reviews Cancer.
[31] C Eng,et al. The relationship between specific RET proto-oncogene mutations and disease phenotype in multiple endocrine neoplasia type 2. International RET mutation consortium analysis. , 1996, JAMA.
[32] S. Borrego,et al. Molecular analysis of the ret and GDNF genes in a family with multiple endocrine neoplasia type 2A and Hirschsprung disease. , 1998, The Journal of clinical endocrinology and metabolism.
[33] C. Eng,et al. Predictors and prevalence of paraganglioma syndrome associated with mutations of the SDHC gene. , 2005, JAMA.
[34] S. Egawa,et al. A nationwide clinical survey of patients with multiple endocrine neoplasia type 2 and familial medullary thyroid carcinoma in Japan. , 1997, Japanese journal of clinical oncology.